Lamm D L, DeHaven J I, Shriver J, Sarosdy M F
Department of Urology, West Virginia University Health Sciences Center, Morgantown.
J Urol. 1991 Apr;145(4):738-40. doi: 10.1016/s0022-5347(17)38439-2.
Conflicting reports of the necessity for percutaneous bacillus Calmette-Guerin (BCG) administration with intravesical BCG prompted us to evaluate its benefit in a randomized prospective comparison of intravesical versus intravesical with percutaneous BCG therapy. Intravesical Tice BCG was given in a dose of 50 mg. with or without percutaneous BCG weekly for 6 weeks, at 8, 10 and 12 weeks, at 6 months and every 6 months thereafter. Tumor recurrence was documented in 13 of 30 patients (43%) receiving only intravesical BCG and in 15 of 36 patients (42%) receiving intravesical plus percutaneous BCG. The addition of percutaneous BCG to intravesical therapy did not increase treatment efficacy in this study.
关于膀胱内灌注卡介苗（BCG）时是否需要经皮给予BCG存在相互矛盾的报道，这促使我们在一项随机前瞻性比较中评估经皮给予BCG与单纯膀胱内灌注BCG治疗的益处。膀胱内给予蒂氏BCG，剂量为50mg，每周一次，持续6周，分别在第8、10和12周、6个月时给予，之后每6个月给予一次，无论是否同时经皮给予BCG。仅接受膀胱内BCG治疗的30例患者中有13例（43%）出现肿瘤复发，接受膀胱内加经皮BCG治疗的36例患者中有15例（42%）出现肿瘤复发。在本研究中，膀胱内治疗加用经皮BCG并未提高治疗效果。
